These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 27576310

  • 1. Protocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal women.
    Bilek LD, Waltman NL, Lappe JM, Kupzyk KA, Mack LR, Cullen DM, Berg K, Langel M, Meisinger M, Portelli-Trinidad A, Lang M.
    BMC Womens Health; 2016 Aug 30; 16(1):59. PubMed ID: 27576310
    [Abstract] [Full Text] [Related]

  • 2. Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
    Waltman N, Kupzyk KA, Flores LE, Mack LR, Lappe JM, Bilek LD.
    Osteoporos Int; 2022 Feb 30; 33(2):475-486. PubMed ID: 34519832
    [Abstract] [Full Text] [Related]

  • 3. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
    Waltman NL, Twiss JJ, Ott CD, Gross GJ, Lindsey AM, Moore TE, Berg K, Kupzyk K.
    Osteoporos Int; 2010 Aug 30; 21(8):1361-9. PubMed ID: 19802506
    [Abstract] [Full Text] [Related]

  • 4. Twelve-month resistance and impact exercise program or risedronate provides a relative benefit to hip bone structure in postmenopausal women: results from a randomized controlled trial.
    Blay R, Flores LE, Kupzyk K, Waltman N, Lappe J, Mack L, Bilek L.
    Osteoporos Int; 2024 May 30; 35(5):877-891. PubMed ID: 38368307
    [Abstract] [Full Text] [Related]

  • 5. The influence of antiresorptive bone medication on the effect of high-intensity resistance and impact training on osteoporotic fracture risk in postmenopausal women with low bone mass: protocol for the MEDEX-OP randomised controlled trial.
    Fischbacher M, Weeks BK, Beck BR.
    BMJ Open; 2019 Sep 05; 9(9):e029895. PubMed ID: 31492784
    [Abstract] [Full Text] [Related]

  • 6. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov 05; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 05; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 9. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ, Naganathan V, Barton I, Grauer A.
    J Bone Miner Res; 2004 Feb 05; 19(2):323-9. PubMed ID: 14969403
    [Abstract] [Full Text] [Related]

  • 10. Study protocol for the ROLEX-DUO randomised placebo-controlled trial: ROmosozumab Loaded with EXercise - DUal effects on bone and muscle in postmenopausal Osteoporosis and Osteopenia.
    Kumar S, Beck BR, Nery L, Byth K, Elhindi J, Wood C, Fuller OK, Clifton-Bligh RJ, Girgis CM.
    BMJ Open; 2024 Aug 24; 14(8):e086708. PubMed ID: 39181562
    [Abstract] [Full Text] [Related]

  • 11. Bone Mass Outcomes in Patients With Osteoporosis Treated With Risedronate After Alendronate Failure: a 12-Month Follow-Up Study.
    Mendonça LT, Pinheiro MM, Szejnfeld VL, Castro CH.
    J Clin Densitom; 2017 Aug 24; 20(1):44-49. PubMed ID: 27616291
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S, Orio F, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.
    Osteoporos Int; 2005 Sep 24; 16(9):1141-9. PubMed ID: 15928801
    [Abstract] [Full Text] [Related]

  • 13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar 24; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 14. Management of postmenopausal osteoporosis and the prevention of fractures.
    Gambacciani M, Levancini M.
    Panminerva Med; 2014 Jun 24; 56(2):115-31. PubMed ID: 24942322
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
    Ringe JD, Faber H, Farahmand P, Dorst A.
    Rheumatol Int; 2006 Mar 24; 26(5):427-31. PubMed ID: 16001181
    [Abstract] [Full Text] [Related]

  • 16. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P.
    Dan Med Bull; 2002 Feb 24; 49(1):1-18. PubMed ID: 11894721
    [Abstract] [Full Text] [Related]

  • 17. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 24; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 18. Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday.
    Xu LH, Adams-Huet B, Poindexter JR, Maalouf NM.
    Osteoporos Int; 2016 May 24; 27(5):1701-8. PubMed ID: 26642963
    [Abstract] [Full Text] [Related]

  • 19. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS, Chua SS, Chew YY, Chan SP.
    J Clin Pharm Ther; 2011 Oct 24; 36(5):557-67. PubMed ID: 21916908
    [Abstract] [Full Text] [Related]

  • 20. Effect of raloxifene hydrochloride on bone mineral density and bone turnover in Kuwaiti postmenopausal women with osteoporosis.
    Abdelazim IA, Abdelrazak KM, Al-Kadi M, Yehia AH, Nusair BM, Faza MA.
    Arch Osteoporos; 2014 Oct 24; 9():189. PubMed ID: 25037077
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.